Aprogen Biologics에이프로젠바이오로직스
003060 · KOSPI · ₩003060 · 에이프로젠바이오로직스
₩1,394▲ ₩7 (0.50%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩73B | ₩67B | ₩87B | ₩65B | ₩56B |
| Cost of sales | ₩100B | ₩75B | ₩99B | ₩38B | ₩31B |
| Gross profit | −₩27B | −₩7.6B | −₩12B | ₩27B | ₩25B |
| Operating income | −₩60B | −₩53B | −₩57B | −₩5.4B | −₩3.8B |
| Net income | −₩168B | −₩105B | −₩115B | ₩5.6B | ₩9.2B |
| Net income to shareholders | −₩170B | −₩105B | −₩118B | ₩7.8B | ₩8.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩587B | ₩591B | ₩589B | ₩676B | ₩615B |
| Current assets | ₩155B | ₩115B | ₩85B | ₩241B | ₩353B |
| Cash and equivalents | ₩24B | ₩12B | ₩10B | ₩24B | ₩35B |
| Total liabilities | ₩309B | ₩212B | ₩221B | ₩174B | ₩17B |
| Current liabilities | ₩229B | ₩148B | ₩158B | ₩161B | ₩9.4B |
| Borrowings | ₩208B | ₩136B | ₩161B | ₩134B | ₩2.2B |
| Total equity | ₩278B | ₩379B | ₩369B | ₩502B | ₩597B |
| Shareholders' equity | ₩208B | ₩378B | ₩369B | ₩422B | ₩508B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩38B | −₩31B | −₩34B | ₩26B | −₩6.2B |
| Capital spending | ₩9.6B | ₩15B | ₩28B | ₩1.3B | ₩796M |
| Free cash flow | −₩48B | −₩46B | −₩62B | ₩24B | −₩7B |
| Dividends paid | ₩84,588 | — | — | — | — |
Consolidated where available. Amounts in won.
Also known as: Aprogen Biologics / 에이프로젠바이오로직스 / 003060 / KRX:003060
Source: KRX statistical information